Affordable Access

deepdyve-link
Publisher Website

Genetic deletion of a short fragment of glucokinase in rabbit by CRISPR/Cas9 leading to hyperglycemia and other typical features seen in MODY-2.

Authors
  • Song, Yuning1
  • Sui, Tingting1
  • Zhang, Yuxin1
  • Wang, Yong1
  • Chen, Mao1
  • Deng, Jichao1
  • Chai, Zhonglin2
  • Lai, Liangxue3
  • Li, Zhanjun4
  • 1 Jilin Provincial Key Laboratory of Animal Embryo Engineering, Jilin University, Changchun, 130062, China. , (China)
  • 2 Department of Diabetes, Central Clinical School, Pathophysiology of Diabetic Complications Laboratory, Monash University, Melbourne, Australia. , (Australia)
  • 3 Jilin Provincial Key Laboratory of Animal Embryo Engineering, Jilin University, Changchun, 130062, China. [email protected] , (China)
  • 4 Jilin Provincial Key Laboratory of Animal Embryo Engineering, Jilin University, Changchun, 130062, China. [email protected] , (China)
Type
Published Article
Journal
Cellular and Molecular Life Sciences
Publisher
Springer-Verlag
Publication Date
Nov 13, 2019
Identifiers
DOI: 10.1007/s00018-019-03354-4
PMID: 31720743
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Glucokinase (GCK) is a key enzyme in glucose sensing and glycemic regulation. In humans, mutations in the GCK gene cause maturity-onset diabetes of the young 2 (MODY-2), a disease that is characterized by an early-onset and persistent hyperglycemia. It is known that Gck knockout (KO) is lethal in mice with Gck KO mice dying within 2 weeks after birth. Therefore, Gck KO mice are not suitable for preclinical study and have limited suitability to study the pathophysiological role of glucokinase in vivo. Here, we report the generation of a novel rabbit with a non-frameshift mutation of GCK gene (GCK-NFS) by cytoplasm microinjection of Cas9 mRNA and gRNA. These GCK-NFS rabbits showed typical features of MODY-2 including hyperglycemia and glucose intolerance with similar survival rate and weight compared to wild-type (WT) rabbits. The diabetic phenotype including pancreatic and renal dysfunction was also found in the F1-generation rabbits, indicating that the genetic modification is germline transmissible. Treatment of GCK-NFS rabbit with glimepiride successfully reduced the fasting blood glucose drastically and improved its islet function. In conclusion, this novel GCK mutant rabbit generated with the CRISPR/Cas9 system mimics most, if not all, histopathological and functional defects seen in MODY-2 patients such as hyperglycemia and will be a valuable rabbit model for preclinical studies and drug screening for diabetes as well as for studying the pathophysiological role of glucokinase.

Report this publication

Statistics

Seen <100 times